Corneal Neovascularization and the Utility of Topical VEGF Inhibition: Ranibizumab (Lucentis) vs Bevacizumab (Avastin)
Ocular Surface - United States
doi 10.1016/j.jtos.2012.01.005
Full Text
Open PDFAbstract
Available in full text
Categories
Date
April 1, 2012
Authors
Publisher
Elsevier BV